MedTrace Logo

Open Label Study of BAY1082439 in Patients With Advanced Cancer

NCT01728311 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-01-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439

Conditions

  • Neoplasms

Interventions

DRUG

BAY1082439

BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-21
Primary Completion
2016-06-03
Completion
2017-02-06

Countries

  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01728311 on ClinicalTrials.gov